Plasminogen Activator Inhibitor-1 Is Involved in Streptozotocin-Induced Bone Loss in Female Mice

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIG. 5.
FIG. 5.

Effects of active PAI-1 treatment on osteoblast differentiation and mineralization in primary osteoblasts from WT mouse calvaria. For RNA analysis and measurement of ALP activity, primary osteoblasts were treated with either vehicle or active PAI-1 (2 nmol/L and 20 nmol/L; Molecular Innovations) for 24 h. Then, total cellular RNA was extracted for gene expression analysis by real-time PCR. ALP activity was measured using Labassay ALP (Wako Pure Industry, Osaka, Japan). Levels of Runx2, osterix, and ALP mRNA in primary osteoblasts from male (A) and female (B) WT mice treated with vehicle or active PAI-1 (2 nmol/L or 20 nmol/L) for 24 h. Data are expressed relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA values and expressed as means ± SEM. **P < 0.01 (n = 3 in each group). ALP activity (C) in primary osteoblasts from male and female WT mouse calvaria treated with vehicle or active PAI-1 (20 nmol/L) for 24 h. Mineralization as assessed by alizarin red staining of primary osteoblasts (D) from male and female WT mouse calvaria cultured in osteogenic medium (MEM α, containing 10 mmol/L β-glycerophosphate and 50 μg/mL ascorbic acid) for 21 days treated with vehicle or active PAI-1 (20 nmol/L). Results are expressed as means ± SEM. **P < 0.01 (n = 3 in each group).

This Article

  1. Diabetes vol. 62 no. 9 3170-3179